Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Single-Donor NAT Filings Should Not Delay Minipool PLAs - Roche, Gen-Probe

This article was originally published in The Gray Sheet

Executive Summary

Roche Molecular Systems intends to submit product licensing applications (PLA's) for both minipool and individual donation nucleic acid test (NAT) assays for HCV and HIV in the first quarter of 2000, James Gallarda, PhD, the firm's blood screening program director, said at a Center for Biologics Evaluation and Research-sponsored workshop on the implementation of nucleic acid testing Dec. 14 in Bethesda, Maryland.

You may also be interested in...



Co-sponsorships To Bring Faster FDA Review, Inspection To New Technology

A May 22-25 course to instruct FDA scientific reviewers and field investigators on nucleic acid amplification testing (NAT) technology is one of several FDA/industry co-sponsorship activities planned for upcoming months.

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel